Nature communications
Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial.
Houyu Ju, Yunteng Wu, Chaoji Shi, Ronghui Xia, Hao Song, Xuhui Ma, Yang Liu, Lulu Sun, Ling Zhu, Lingyan Chen, Shuyang Sun, Yue He, Guoxin Ren, Jingzhou Hu
Published: 202610.1038/s41467-026-68736-2
Abstract
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is characterised by hyperactivation of the cyclin-dependent kinase 4/6 (CDK4/6) pathway. As immunotherapy has become the first-line treatment for HNSCC, resistance to a…
Preview only. Read the full abstract at the source